Corcept Therapeutics (CORT) is highlighted as one of the best biotech stocks to buy by Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $145 price target on November 25, emphasizing strong growth prospects despite commercial challenges.

The company’s Korlym medication is projected to see sales growth of 19% to 26% year over year, with strong demand driving a 40% increase in volume over the past two quarters. Corcept is poised to meet its guidance of $800-$850 million in sales.

Wolfe Research initiated coverage of CORT with a Peer Perform rating on November 17. Analyst Kalpit Patel sees potential in the upcoming relacorilant drug for hypercortisolism, but remains cautious on peak sales outlook due to legal hurdles. The stock is expected to trade in the $70-$75 range.

Corcept Therapeutics (CORT) develops drugs targeting cortisol to treat various disorders. Their first approved drug, Korlym, treats Cushing’s Syndrome. Their pipeline includes treatments for cancers, ALS, and liver diseases.

While CORT shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. For those seeking undervalued AI stocks, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects